Evidence map›Paper›PMID 35221905›Full record

ReviewFrontiers in neuroscience2022

Macromolecular Proton Fraction as a Myelin Biomarker: Principles, Validation, and Applications.

Alena A Kisel, Anna V Naumova, Vasily L Yarnykh

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 37 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Evaluation of Articular Cartilage in Knee Osteoarthritis Using Macromolecular Proton Fraction Mapping.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Article
  6. Article
  7. Diagnostic Potential of Macromolecular Proton Fraction Mapping Combined with Quantitative Susceptibility Mapping as a Subcortical Biomarker for Parkinson's Disease.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2026
    Article
  8. Article
  9. Multimodal MEG and Microstructure-MRI Investigations of the Human Hippocampal Scene Network.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Demyelination in Patients with POST-COVID Depression.Journal of clinical medicine · 2024
    Article
  14. Review
  15. Article
  16. Imaging of the superficial white matter in health and disease.Imaging neuroscience (Cambridge, Mass.) · 2024
    Article
  17. Article
  18. Language Environment and Infants' Brain Structure.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2023
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Alena A KiselDepartment of Radiology, University of Washington, Seattle, WA, United States.
Anna V NaumovaDepartment of Radiology, University of Washington, Seattle, WA, United States.
Vasily L YarnykhDepartment of Radiology, University of Washington, Seattle, WA, United States.
University of Washington · US

Funding

Quantitative myelin mapping in vivo for clinical and pre-clinical MRIR24NS104098 · NINDS · UNIVERSITY OF WASHINGTON · PI YARNYKH, VASILY L. · 2018 to 2021
$1.1M
Preclinical MRI of demyelination and remyelination in stroke at clinical field strengthR21NS109727 · NINDS · UNIVERSITY OF WASHINGTON · PI YARNYKH, VASILY L. · 2019 to 2019
$485k
NINDS NIH HHS R21 NS109727NINDS NIH HHS R24 NS104098
6 · The paper itself

Abstract

Macromolecular proton fraction (MPF) is a quantitative MRI parameter describing the magnetization transfer (MT) effect and defined as a relative amount of protons bound to biological macromolecules with restricted molecular motion, which participate in magnetic cross-relaxation with water protons. MPF attracted significant interest during past decade as a biomarker of myelin. The purpose of this mini review is to provide a brief but comprehensive summary of MPF mapping methods, histological validation studies, and MPF applications in neuroscience. Technically, MPF maps can be obtained using a variety of quantitative MT methods. Some of them enable clinically reasonable scan time and resolution. Recent studies demonstrated the feasibility of MPF mapping using standard clinical MRI pulse sequences, thus substantially enhancing the method availability. A number of studies in animal models demonstrated strong correlations between MPF and histological markers of myelin with a minor influence of potential confounders. Histological studies validated the capability of MPF to monitor both demyelination and re-myelination. Clinical applications of MPF have been mainly focused on multiple sclerosis where this method provided new insights into both white and gray matter pathology. Besides, several studies used MPF to investigate myelin role in other neurological and psychiatric conditions. Another promising area of MPF applications is the brain development studies. MPF demonstrated the capabilities to quantitatively characterize the earliest stage of myelination during prenatal brain maturation and protracted myelin development in adolescence. In summary, MPF mapping provides a technically mature and comprehensively validated myelin imaging technology for various preclinical and clinical neuroscience applications.

Indexed as

braincentral nervous systemmacromolecular proton fraction (MPF)magnetization transfer (MT)MRImyelinquantitative imagingspinal cord

Identifiers

PMID35221905
PMCPMC8863973
OpenAlexW4211047836

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.